Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Tennessee: - Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Tennessee: - East Tennessee Childrens Hospital — Knoxville, Tennessee
- Saint Jude Children's Research Hospital — Memphis, Tennessee
- The Children's Hospital at TriStar Centennial — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harborin…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Tennessee: - SCRI - TriStar Medical Group Children's Specialists — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
NCT ID: NCT06701812
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05535166
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Tennessee: - Monroe Carrell Jr. Children's Hospital at Vanderbilt — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population i…
Sponsor: LigaChem Biosciences, Inc.
NCT ID: NCT05941507
Sites in Tennessee: - Tennessee Oncology — Nashville, Tennessee
Phase 2 Recruiting Academic/Other
This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called ki…
Sponsor: University of California, San Francisco
NCT ID: NCT07110246
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1, Phase 2 Recruiting Industry
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…
Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Phase 2 Recruiting Industry
This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The …
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06061809
Sites in Tennessee: - Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
Phase 1, Phase 2 Recruiting Academic/Other
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04923126
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …
Sponsor: Pfizer
NCT ID: NCT05355701
Sites in Tennessee: - Sarah Cannon Research Institute - Pharmacy — Nashville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
- TriStar Bone Marrow Transplant — Nashville, Tennessee
- TriStar Centennial Medical Center - Cell Processing Lab — Nashville, Tennessee
- TriStar Centennial Medical center — Nashville, Tennessee
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Tennessee: - SCRI Oncology Partners — Nashville, Tennessee
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee
Phase 1 Recruiting Network
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or…
Sponsor: Children's Oncology Group
NCT ID: NCT06894979
Sites in Tennessee: - Saint Jude Children's Research Hospital — Memphis, Tennessee
Phase 1 Recruiting Industry
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after stand…
Sponsor: RasCal Therapeutics, Inc.
NCT ID: NCT04678648
Sites in Tennessee: - Sarah Cannon, SCRI Oncology Partners — Nashville, Tennessee
Phase 1 Recruiting Academic/Other
Loc3CAR is a Phase I clinical trial evaluating the use of autologous B7-H3-CAR T cells for participants ≤ 21 years old with primary CNS neoplasms. B7-H3-CAR T cells will be locoregionally administered via a CNS reservoir catheter. Study pa…
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT05835687
Sites in Tennessee: - St. Jude Children's Research Hospital — Memphis, Tennessee
EARLY Phase 1 Recruiting Academic/Other
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Sponsor: Vanderbilt-Ingram Cancer Center
NCT ID: NCT05996432
Sites in Tennessee: - Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
EARLY Phase 1 Recruiting Academic/Other
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patien…
Sponsor: Eben Rosenthal
NCT ID: NCT07210632
Sites in Tennessee: - Vanderbilt University Medical Center — Nashville, Tennessee
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Tennessee: - Massive Bio SYNERGY-AI site — Memphis, Tennessee
- Massive Bio SYNERGY-AI site — Nashville, Tennessee